Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00102531 · ClinicalTrials.gov registry record · Phase 1
Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung
A Phase 1 study of Osteosarcoma Metastatic, sponsored by Insmed Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 2
- Study locations
NCT00102531 is a Phase 1 study of Osteosarcoma Metastatic that has completed, run by Insmed Incorporated. The registered enrollment target is 19 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT00102531, a Phase 1 study of Osteosarcoma Metastatic, has completed, sponsored by Insmed Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 2
- Study locations
Study Summary
Phase Ib/IIa open label safety and efficacy study designed to determine the maximum tolerated dose of inhaled cisplatin liposomal (SLIT cisplatin) administered every 14 days to patients with relapsed/progressive osteosarcoma metastatic to the lung.
Conditions Studied
Interventions
- DRUG Cisplatin liposomal
Study Locations (2)
New York
- Memorial Sloan Kettering Cancer Center - New York
- The Albert Einstein College of Medicine Montefiore Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2005-01-12 |
| Est. Completion | 2008-03-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00102531
The ClinicalTrials.gov registry entry for NCT00102531 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Insmed Incorporated, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteosarcoma Metastatic appearing as the primary indexed condition, and to 1 intervention - of which Cisplatin liposomal is the first listed.
NCT00102531 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00102531 about?
NCT00102531 is a clinical study titled "Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung". Phase Ib/IIa open label safety and efficacy study designed to determine the maximum tolerated dose of inhaled cisplatin liposomal (SLIT cisplatin) administered every 14 days to patients with relapsed/progressive osteosarcoma metastatic to the lung.
What is the current status of trial NCT00102531?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2005-01-12. Estimated completion is 2008-03-17.
What conditions does trial NCT00102531 study?
This clinical trial studies the following conditions: Osteosarcoma Metastatic.
What interventions are being tested in trial NCT00102531?
The interventions under investigation include: Cisplatin liposomal (DRUG).
Who is sponsoring clinical trial NCT00102531?
This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00102531 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteosarcoma Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.